Bridge Biotherapeutics enrols all subjects in idiopathic pulmonary fibrosis drug trial - Yahoo Finance
288330 Stock | KRW 3,955 95.00 2.35% |
About 61% of Bridge Biotherapeutics' investor base is looking to short. The analysis of current outlook of investing in Bridge Biotherapeutics suggests that many traders are alarmed regarding Bridge Biotherapeutics' prospects. The current market sentiment, together with Bridge Biotherapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Bridge Biotherapeutics stock news signals to limit their universe of possible portfolio assets.
Bridge |
Bridge Biotherapeutics enrols all subjects in idiopathic pulmonary fibrosis drug trial Yahoo Finance
Read at news.google.com
Bridge Biotherapeutics Fundamental Analysis
We analyze Bridge Biotherapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bridge Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bridge Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
Bridge Biotherapeutics is rated fifth in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Bridge Biotherapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Bridge Biotherapeutics stock to make a market-neutral strategy. Peer analysis of Bridge Biotherapeutics could also be used in its relative valuation, which is a method of valuing Bridge Biotherapeutics by comparing valuation metrics with similar companies.
Peers
Bridge Biotherapeutics Related Equities
278650 | KNOTUS CoLtd | 0.51 | ||||
288330 | Bridge Biotherapeutics | 2.35 | ||||
225220 | Genolution | 2.39 | ||||
215380 | WOOJUNG BIO | 3.22 | ||||
217330 | Cytogen | 8.00 |
Complementary Tools for Bridge Stock analysis
When running Bridge Biotherapeutics' price analysis, check to measure Bridge Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bridge Biotherapeutics is operating at the current time. Most of Bridge Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bridge Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bridge Biotherapeutics' price. Additionally, you may evaluate how the addition of Bridge Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Stocks Directory Find actively traded stocks across global markets | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |